Checkpoint Therapeutics (CKPT) Projected to Post Earnings on Friday

Checkpoint Therapeutics (NASDAQ:CKPT) is expected to be announcing its earnings results before the market opens on Friday, March 28th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter.

Checkpoint Therapeutics Stock Performance

Shares of Checkpoint Therapeutics stock opened at $4.06 on Wednesday. Checkpoint Therapeutics has a fifty-two week low of $1.38 and a fifty-two week high of $4.50. The company has a market cap of $198.26 million, a P/E ratio of -2.21 and a beta of 1.41. The firm has a 50-day simple moving average of $3.27 and a two-hundred day simple moving average of $3.23.

Insider Buying and Selling at Checkpoint Therapeutics

In related news, CFO William Garrett Gray sold 74,110 shares of the business’s stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $3.67, for a total transaction of $271,983.70. Following the completion of the sale, the chief financial officer now owns 1,458,644 shares in the company, valued at $5,353,223.48. The trade was a 4.84 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO James F. Oliviero III sold 9,233 shares of the stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $3.41, for a total transaction of $31,484.53. Following the completion of the transaction, the chief executive officer now owns 3,785,350 shares in the company, valued at $12,908,043.50. This represents a 0.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 93,674 shares of company stock worth $336,011 over the last three months. Insiders own 2.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Lake Street Capital reiterated a “hold” rating and issued a $4.10 target price (down previously from $7.00) on shares of Checkpoint Therapeutics in a research report on Monday, March 10th. HC Wainwright reaffirmed a “neutral” rating and set a $4.10 target price on shares of Checkpoint Therapeutics in a report on Tuesday, March 11th. Finally, D. Boral Capital reissued a “buy” rating and issued a $4.80 price target (down from $9.00) on shares of Checkpoint Therapeutics in a research note on Monday, March 10th.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.